Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Assets (2017 - 2026)

Denali Therapeutics has reported Other Non-Current Assets over the past 9 years, most recently at $25.9 million for Q4 2025.

  • Quarterly Other Non-Current Assets rose 4.84% to $25.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.9 million through Dec 2025, up 4.84% year-over-year, with the annual reading at $25.9 million for FY2025, 4.84% up from the prior year.
  • Other Non-Current Assets was $25.9 million for Q4 2025 at Denali Therapeutics, up from $25.1 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $50.6 million in Q2 2024 and troughed at $3.6 million in Q2 2021.
  • The 5-year median for Other Non-Current Assets is $15.7 million (2022), against an average of $19.3 million.
  • Year-over-year, Other Non-Current Assets surged 382.17% in 2021 and then plummeted 54.58% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $11.9 million in 2021, then increased by 12.87% to $13.4 million in 2022, then surged by 35.41% to $18.1 million in 2023, then skyrocketed by 36.37% to $24.7 million in 2024, then grew by 4.84% to $25.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Other Non-Current Assets are $25.9 million (Q4 2025), $25.1 million (Q3 2025), and $23.0 million (Q2 2025).